Your browser doesn't support javascript.
loading
Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
Petri, M A; Martin, R S; Scheinberg, M A; Furie, R A.
Affiliation
  • Petri MA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Martin RS; Medical Sciences, Anthera Pharmaceuticals Inc, Hayward, CA, USA rmartin@anthera.com.
  • Scheinberg MA; Clinical Research Center, Hospital Abreu Sodré-AACD, São Paulo, Brazil.
  • Furie RA; Division of Rheumatology and Allergy-Clinical Immunology, North Shore-Long Island Jewish Health System, Great Neck, NY, USA.
Lupus ; 26(1): 27-37, 2017 Jan.
Article in En | MEDLINE | ID: mdl-27353505
Subject(s)
Key words
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Fatigue / Immunologic Factors / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Etiology_studies Limits: Adult / Female / Humans / Male Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Fatigue / Immunologic Factors / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Etiology_studies Limits: Adult / Female / Humans / Male Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication: